Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma
Pediatric osteosarcoma, the most prevalent primary malignant bone tumor in children, is marked by aggressive progression and a generally poor prognosis. Despite advances in treatment, including multi-agent chemotherapy, survival rates remain suboptimal…